202 related articles for article (PubMed ID: 27482723)
1. Peripherally Selective Cannabinoid 1 Receptor (CB1R) Agonists for the Treatment of Neuropathic Pain.
Seltzman HH; Shiner C; Hirt EE; Gilliam AF; Thomas BF; Maitra R; Snyder R; Black SL; Patel PR; Mulpuri Y; Spigelman I
J Med Chem; 2016 Aug; 59(16):7525-43. PubMed ID: 27482723
[TBL] [Abstract][Full Text] [Related]
2. A peripherally restricted cannabinoid receptor agonist produces robust anti-nociceptive effects in rodent models of inflammatory and neuropathic pain.
Yu XH; Cao CQ; Martino G; Puma C; Morinville A; St-Onge S; Lessard É; Perkins MN; Laird JMA
Pain; 2010 Nov; 151(2):337-344. PubMed ID: 20696525
[TBL] [Abstract][Full Text] [Related]
3. CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.
Deng L; Cornett BL; Mackie K; Hohmann AG
Mol Pharmacol; 2015 Jul; 88(1):64-74. PubMed ID: 25904556
[TBL] [Abstract][Full Text] [Related]
4. MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models.
Naguib M; Diaz P; Xu JJ; Astruc-Diaz F; Craig S; Vivas-Mejia P; Brown DL
Br J Pharmacol; 2008 Dec; 155(7):1104-16. PubMed ID: 18846037
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain.
Diaz P; Xu J; Astruc-Diaz F; Pan HM; Brown DL; Naguib M
J Med Chem; 2008 Aug; 51(16):4932-47. PubMed ID: 18666769
[TBL] [Abstract][Full Text] [Related]
6. Synthetic peripherally-restricted cannabinoid suppresses chemotherapy-induced peripheral neuropathy pain symptoms by CB1 receptor activation.
Mulpuri Y; Marty VN; Munier JJ; Mackie K; Schmidt BL; Seltzman HH; Spigelman I
Neuropharmacology; 2018 Sep; 139():85-97. PubMed ID: 29981335
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.
Davis MP
Expert Opin Investig Drugs; 2014 Aug; 23(8):1123-40. PubMed ID: 24836296
[TBL] [Abstract][Full Text] [Related]
8. 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects.
De Vry J; Denzer D; Reissmueller E; Eijckenboom M; Heil M; Meier H; Mauler F
J Pharmacol Exp Ther; 2004 Aug; 310(2):620-32. PubMed ID: 15140913
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging.
Yao BB; Hsieh G; Daza AV; Fan Y; Grayson GK; Garrison TR; El Kouhen O; Hooker BA; Pai M; Wensink EJ; Salyers AK; Chandran P; Zhu CZ; Zhong C; Ryther K; Gallagher ME; Chin CL; Tovcimak AE; Hradil VP; Fox GB; Dart MJ; Honore P; Meyer MD
J Pharmacol Exp Ther; 2009 Jan; 328(1):141-51. PubMed ID: 18931146
[TBL] [Abstract][Full Text] [Related]
10. Recent development of CB2 selective and peripheral CB1/CB2 cannabinoid receptor ligands.
Nevalainen T
Curr Med Chem; 2014; 21(2):187-203. PubMed ID: 24164198
[TBL] [Abstract][Full Text] [Related]
11. Fluorinated CRA13 analogues: Synthesis, in vitro evaluation, radiosynthesis, in silico and in vivo PET study.
Hassan AHE; Park KT; Kim HJ; Lee HJ; Kwon YH; Hwang JY; Jang CG; Chung JH; Park KD; Lee SJ; Oh SJ; Lee YS
Bioorg Chem; 2020 Jun; 99():103834. PubMed ID: 32334193
[TBL] [Abstract][Full Text] [Related]
12. A Cannabinoid CB1 Receptor-Positive Allosteric Modulator Reduces Neuropathic Pain in the Mouse with No Psychoactive Effects.
Ignatowska-Jankowska BM; Baillie GL; Kinsey S; Crowe M; Ghosh S; Owens RA; Damaj IM; Poklis J; Wiley JL; Zanda M; Zanato C; Greig IR; Lichtman AH; Ross RA
Neuropsychopharmacology; 2015 Dec; 40(13):2948-59. PubMed ID: 26052038
[TBL] [Abstract][Full Text] [Related]
13. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models.
Jayamanne A; Greenwood R; Mitchell VA; Aslan S; Piomelli D; Vaughan CW
Br J Pharmacol; 2006 Feb; 147(3):281-8. PubMed ID: 16331291
[TBL] [Abstract][Full Text] [Related]
14. Characterization of cannabinoid-induced relief of neuropathic pain in a rat model of cisplatin-induced neuropathy.
Vera G; Cabezos PA; Martín MI; Abalo R
Pharmacol Biochem Behav; 2013 Apr; 105():205-12. PubMed ID: 23454533
[TBL] [Abstract][Full Text] [Related]
15. Novel pyridine derivatives as potent and selective CB2 cannabinoid receptor agonists.
Chu GH; Saeui CT; Worm K; Weaver DG; Goodman AJ; Broadrup RL; Cassel JA; DeHaven RN; LaBuda CJ; Koblish M; Brogdon B; Smith S; Le Bourdonnec B; Dolle RE
Bioorg Med Chem Lett; 2009 Oct; 19(20):5931-5. PubMed ID: 19736007
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists.
Yrjölä S; Sarparanta M; Airaksinen AJ; Hytti M; Kauppinen A; Pasonen-Seppänen S; Adinolfi B; Nieri P; Manera C; Keinänen O; Poso A; Nevalainen TJ; Parkkari T
Eur J Pharm Sci; 2015 Jan; 67():85-96. PubMed ID: 25447744
[TBL] [Abstract][Full Text] [Related]
17. Self-medication of a cannabinoid CB2 agonist in an animal model of neuropathic pain.
Gutierrez T; Crystal JD; Zvonok AM; Makriyannis A; Hohmann AG
Pain; 2011 Sep; 152(9):1976-1987. PubMed ID: 21550725
[TBL] [Abstract][Full Text] [Related]
18. Effects of gonadal hormones on the peripheral cannabinoid receptor 1 (CB1R) system under a myositis condition in rats.
Niu KY; Zhang Y; Ro JY
Pain; 2012 Nov; 153(11):2283-2291. PubMed ID: 22940464
[TBL] [Abstract][Full Text] [Related]
19. Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist.
Brizzi A; Aiello F; Marini P; Cascio MG; Corelli F; Brizzi V; De Petrocellis L; Ligresti A; Luongo L; Lamponi S; Maione S; Pertwee RG; Di Marzo V
Bioorg Med Chem; 2014 Sep; 22(17):4770-83. PubMed ID: 25065940
[TBL] [Abstract][Full Text] [Related]
20. Discovery and optimization of 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives as a novel class of selective cannabinoid CB2 receptor agonists.
van der Stelt M; Cals J; Broeders-Josten S; Cottney J; van der Doelen AA; Hermkens M; de Kimpe V; King A; Klomp J; Oosterom J; Pols-de Rooij I; de Roos J; van Tilborg M; Boyce S; Baker J
J Med Chem; 2011 Oct; 54(20):7350-62. PubMed ID: 21923175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
